Nurix Therapeutics Inc reports results for the quarter ended in August - Earnings Summary

Nurix Therapeutics

12/10/2023 22:01

* Nurix Therapeutics Inc  NRIX.OQ  reported a quarterly
adjusted
loss of 68 cents​​ per share for the quarter ended in August.
The mean expectation of twelve analysts for the quarter was
for a loss of 76 cents per share.
    * Revenue rose 71.1% to $18.47 million from a year ago;
analysts
expected $17.23 million. 
    * Nurix Therapeutics Inc's reported EPS for the quarter was
a loss
of 68 cents​.
    * The mean earnings estimate of analysts had risen by
about 13.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Nurix Therapeutics Inc shares had fallen by 15.6% this
quarter and lost 39.6% so far this year.
    * The company reported a quarterly loss of $36.98 million.
    * Wall Street's median 12-month price target for Nurix
Therapeutics Inc is $29.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
October 12 at 09:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Aug. 31 2023      -0.76          -0.68          Beat
 May. 31 2023      -0.56          -0.45          Beat
 Feb. 28 2023      -0.87          -0.75          Beat
 Nov. 30 2022      -0.79          -0.87          Missed